Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza.
Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line results from a head-to-head trial between its once-weekly Type 2 diabetes remedy and the once-daily Victoza (liraglutide). And dulaglutide stood its own.
Eli Lilly says its closely-watched GLP-1 diabetes drug dulaglutide works as well as the market leading therapy Victoza, but isn't superior to the rival drug. That's going to be good enough for Lilly to claim a big win, though, as analysts were ready to hand it a victory on non-inferiority for a drug now in the hands of regulators.
After a high-profile breast cancer failure bit into its potential sales, Eli Lilly's ramucirumab aced a Phase III study in lung cancer, renewing hopes that the star of the drugmaker's oncology pipeline can still deliver on its promise.
Sanofi and its top-selling Lantus may have bought some time last month with a legal wrench in Eli Lilly's spokes, but now Merck has bulldozed its way into the conversation with plans to kick off late-stage studies for its own knockoff of the blockbuster drug, further complicating an already heated fight.
Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Sanofi's got the top-selling diabetes drug in the world right now, and it intends to keep it that way. The French drugmaker is suing Eli Lilly over infringement claims on four of the patents for its Lantus insulin product, which is set to lose protection next February.
You can scratch Eli Lilly's copycat version of Lantus off its short list of near-term approval prospects. Sanofi says it has filed a lawsuit against Lilly claiming that the pharma rival infringed four of its patents, which is likely to delay any launch until the middle of 2016.